

Publication policy CONTRAST

Version Q1 2026

The overall aim of the publication policy is 1) to stimulate, harmonize and streamline high-quality scientific output from the CONTRAST project and 2) to fulfil the contractual commitments done to partners and funders.

This procedure is applicable to all studies, from single or multiple workpackages, that concern the CONTRAST consortium, or will be submitted on behalf of the CONTRAST collaborators. This includes studies using patient data collected within CONTRAST, but also experimental studies, reviews, protocols and opinion papers.

Specific aims:

- Maximize the quality of scientific output, where appropriate harmonization of methods
- Increase efficiency and avoid duplication of research within CONTRAST
- Define authorship criteria, fostering the involvement of different entities participating in CONTRAST in the scientific outputs
- Maintain transparency within the consortium
- Ensure identification of the CONTRAST consortium and its members as the publication source where appropriate
- Ensure acknowledgements of the funders of the CONTRAST consortium
- Facilitate analyses on data from multiple work packages
- Share descriptions of common procedures, criteria and analyses
- Promote early sharing of detailed results of analyses, for others to anticipate on in follow-up publications.

Guidelines for publications

- For papers concerning solely content from 1 workpackage: WP leaders from that work-package suffice as representation of the scientific committee.
- For papers on data from multiple workpackages: at least two collaborators, including the WP leaders from each of these workpackages should be invited to become author; they can propose other WP collaborators to replace them.
- Lead authors should be encouraged to invite collaborators from other workpackages as authors, to increase cohesion in the consortium and improve the quality of our output.
- Workpackage leaders should make clear and explicit agreements about the order of authors on the paper, particularly about first, second, last and shared first or last authorships.
- All authors should meet [ICMJE criteria for authorship](#), please click this link and advise your co-authors about these criteria.
- Authors should be given the opportunity to adhere to the ICMJE criteria by involving them in an early stage (e.g. by sending abstract and tables and figures for review, or a first draft , with sufficient time to edit and respond, i.e., 4 weeks at minimum.
- Lack of adherence to the ICMJE criteria means that authors should be removed from the author list and added as collaborators instead.

- All investigators that contribute to a particular study should be invited to become co-author on the paper that reports the results concerning the primary research question of that study. A list of all collaborators of the specific RCT should be available and up to date.
- On other papers using data from the aforementioned WP study, the collaborators of should be acknowledged as collaborators in such a way that they will be recognized and can be found on [Pubmed.gov](https://pubmed.gov). This is usually accomplished by providing the journal with an appendix, with all collaborators and their affiliations, to be published online and linked with Pubmed.
- The CONTRAST consortium should be acknowledged on all publications, using standard formulations on Plaza. Acknowledgments and disclosures are very important. See template for Acknowledgments and disclosures in part 3 of this document, which is the source document for the template on the Plaza.
- Standard texts on availability of data from CONTRAST studies for other parties are found below.

*Collaborator lists should be made available by WP leaders for all studies in CONTRAST and MR CLEAN. This includes MR CLEAN, MR CLEAN Registry, MR CLEAN MED, MR CLEAN NOIV, LATE, the DIST and MR ASAP, including collaborators (executive committee, local PI's, outcome core, imaging core, statistician, labs, etc.) of the RCT, and made available through the contrast plaza. [Collaborator list consolidated April 2026.xlsx](#)

Publication Checklist

- Study Plan was approved?
- Is "CONTRAST" recognizable in the title/subtitle/authorslist?
- Are the appropriate funding sources mentioned?
- Appropriate lists of authors and collaborators included reflecting contribution made to the manuscript?
- Data analytic methods agree with main CONTRAST publication on these data (handling of patient selection and missing data, multivariable approach, reporting of associations)
- Data analysis performed in anDREa?
- Sponsor informed if required?
- All authors meeting ICMJE criteria?

Procedure

1. Researchers send the final manuscript and the target journal to dawc.contrast@contrastconsortium.nl **before submitting to a journal.**
2. Publication committee checks content (marginal) and adherence to Guidelines for Publication
3. **Sponsor checks** on technical accuracy, error corrections or release of companies IP or confidential information
4. **Feedback** or approval is sent to researcher by DAWC secretary, **within 14 days** after receipt of the manuscript.
5. Only **after approval** the publication should be **submitted** to a journal
6. Publication will be **listed and accessible** for CONTRAST researchers on plaza

Required texts to be included in scientific papers and presentations concerning data from the CONTRAST consortium

All publications need an acknowledgment of the CONTRAST consortium and its funders. We propose texts and these will often suffice. If you need to adapt the text, please consult the DAWC directly or highlight it when you send your publication to the DAWC prior to submission.

We additionally provide Dutch texts, to be used for national publications.

We distinguish between

- 1) General acknowledgments and disclosures to be used in all publications and presentations.
- 2) WP specific acknowledgements and disclosures
- 3) Statement concerning data-sharing
- 4) Acknowledgment of the CONTRAST WP leaders.

1. Acknowledgement & Disclosure on posters and presentations

Posters

At the bottom of the poster, insert all logo's of funders. At the top, include the CONTRAST logo.

Alternatively, include the acknowledgment text.

Here you can find a poster template: [3. Poster format](#)

Slides

Insert a slide with all logo's of funders as second or last. Use the CONTRAST format ([2. Presentation format](#)), or at least show the contrast logo on the first and last slide in the right upper corner.

A slide with the acknowledgment text is also allowed. We advise you to reserve the last slide for your conclusions & implications, and insert the acknowledgment slide as second.

Logos in presentations:

Include at least the Acknowledgement slide to your presentations with all logos: [Logos.pptx](#)

Manuscripts

For manuscripts, use this acknowledgment and disclosure text:

This research is funded by the Dutch Heart Foundation and The Brain Foundation Netherlands and is conducted in collaboration with and supported by the Dutch CardioVascular Alliance, 01-002-2022-0126 CONTRAST 2.0. In addition, this work was funded in part through unrestricted funding by Stryker, Medtronic and Penumbra. The funding sources were not involved in study design, monitoring, data collection, statistical analyses, interpretation of results, or manuscript writing.

Studies that make use of core-lab assessed CTP data should add the following sentence:

" Leading the Change/Healthcare Evaluation Netherlands provided funding for CTP analysis. "

In text (methods) statement about funding:

This study received unrestricted private/public funding through the CONTRAST consortium.

Dutch publications:

In Dutch publications a brief funding statement should be made in the text, and refer to a footnote.

Het onderzoek ontving publieke en private financiering van onder andere Hartstichting en Hersenstichting, via het CONTRAST Consortium.^[1]

^[1] Dit onderzoek wordt gefinancierd door de Hartstichting en Hersenstichting en wordt uitgevoerd in samenwerking met en ondersteund door de Dutch CardioVascular Alliance, 01-002-2022-0126 CONTRAST 2.0. Daarnaast werd dit werk gedeeltelijk gefinancierd door Stryker, Medtronic en Penumbra. De financierders waren niet betrokken bij het ontwerpen van het onderzoek, het monitoren, de gegevensverzameling, de statistische analyses, de interpretatie van de resultaten of het schrijven van het manuscript.

2. Additional workpackage-specific disclosure or acknowledgement on posters and presentations and in manuscripts.

Workpackages that received separate funding should acknowledge this and add the information to the standard text.

WP3A: MeVO

Check agreement met Basel

WP3B: Cases Benefit

“This report is independent research funded by Belgian Health Care Knowledge Centre and the Dutch Organisation for knowledge and innovation in health, healthcare and well-being (ZonMw): BeNeFIT2, Carotid artery stenting during endovascular treatment of acute ischemic stroke: A randomized multicenter clinical trial in patients with acute ischemic stroke and carotid artery stenosis undergoing endovascular treatment (CASES), 80-87700-98-21561]. The views expressed in this publication are those of the author(s) and not necessarily those of the funders.”

WP3C: IRIS

AMC and Erasmus MC received additional funding on behalf of CONTRAST2 for the execution of this study from Stryker European Operations BV and from Boehringer Ingelheim.

The phrase, “on behalf of the IRIS Collaboration Investigators”, will be included at the end of the author list on all publications. An appendix will be added to the manuscripts with the names of the IRIS Collaboration Investigators, as supplied by the collaboration Executive Committee after acceptance of a study proposal (see Appendix 1

[Complete_with_DocuSign_202309278_reviewed_pr.pdf](#)).

WP4: DIST

Radboud UMC and Erasmus MC received additional unrestricted funding on behalf of CONTRAST2 from Penumbra Inc and from ZonMw/Zorginstituut veelbelovende zorg.

3. Texts about data sharing

Data of this study will be made available upon reasonable request to the corresponding author, usually 12 months after publication of the main results.

4. Acknowledgement of the CONTRAST WP-leaders and collaborators

The starting point is that every publication that makes use of CONTRAST data or CONTRAST infrastructure, should acknowledge CONTRAST. The CONTRAST members do not need to be mentioned in the paper or in an appendix, but the paper should refer to the CONTRAST website (www.contrast-consortium.nl). Also consider adding “CONTRAST Investigators” to the authors list.

However, the main publication of a project, trial or study should list all collaborators who directly contributed to the study and were not included as an author. This collaborator list should be attached to the publication as a supplementary appendix. These collaborators should be made known in PubMed. This includes local PIs of the centers, local coordinators, but also research nurses involved in follow-up, laboratory coordinators, and not to forget, core lab members who assessed the baseline and follow up imaging, and the blinded outcome assessors. Names can be found in the list on the CONTRAST plaza.